Novartis (NVS) today announced that Cosentyx met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx demonstrated statistically significant and clinically ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback